Association of Dipping Pattern or Early Morning Surge of BP With Asymptomatic Episodes of Paroxysmal Atrial Fibrillation in Subjects With Hypertension (DIMOSPAF) (DIMOSPAF)

September 30, 2015 updated by: Emmanuel A. Andreadis, Evangelismos Hospital

Association Between Circadian Blood Pressure Patterns With Asymptomatic Episodes of Paroxysmal Atrial Fibrillation in Hypertensive Subjects

The goals of our study are to determine a).the association between abnormal circadian BP and the development of paroxysmal AF in hypertensive patients, b).at which level of TOD, paroxysmal AF episodes are detected in hypertensive subjects, c).if there is any association between systolic and/or diastolic BP levels with AF occurrence, d).whether the mean heart rate during a 24-hr interval is associated with the development of paroxysmal AF, and finally e).examine the relationship between a wide PP and asymptomatic AF episodes in patients with HTN.

Study Overview

Status

Unknown

Detailed Description

Atrial fibrillation, also known as AF or Afib, is an abnormal and irregular heart rhythm in which electrical signals are generated chaotically throughout the upper chambers (atria) of the heart. According to the NICE clinical guidelines, a patient who experiences recurrent (two or more) AF episodes that terminate spontaneously without any treatment in less than seven days, and usually within 48 hours is classified as having paroxysmal AF. It has been shown that paroxysmal AF comprises approximately between 25% and 62% of cases of AF, and it is estimated that both its incidence and prevalence are likely to rise as the worldwide population ages dramatically over the next twenty years. Interestingly, hospitalizations due to AF have increased sharply in the US during the last decade, posing thereby a heavy economic burden on the health care system and society.

Likewise, hypertension (HTN) also constitutes a major public health problem globally, and its prevalence is set to increase owing to widespread population ageing. This epidemiological trend is especially prevalent in rapidly developing countries where early routine screening at any point of health care is underutilized among risk subjects, due to several perceived barriers. Moreover, HTN awareness is critical for optimal BP control since under-diagnosis, under-treatment and/or un-treatment of high BP levels can have deleterious effects on the cardiovascular system. In addition, HTN is the single most important risk factor for cerebrovascular stroke, and it has been clearly demonstrated that it is also associated with structural and functional changes in the myocardium that favor the development of AF, further increasing the risk of thromboembolism. Among those alterations, left ventricular hypertrophy (LVH), impaired ventricular filling, left atrial enlargement and slowing of atrial conduction velocity have been identified as important heralds of cardiovascular morbidity and mortality. More specifically, since HTN and AF are two conditions that often co-exist, especially in patients with advanced age, the risk for considerable morbidity and mortality is increased even more, which points towards the significance that optimal BP control holds in the prevention of cardiovascular events. To our knowledge, in the Framingham Heart Study, after controlling for age and other predisposing conditions, HTN and diabetes emerged as the only cardiovascular risk factors predicting AF.

It has also been suggested that nocturnal HTN and non-dipping of BP during sleep are distinct entities that often occur together and are regarded as important harbingers of poor cardiovascular prognosis. Recently, Pierdomenico et al., showed that non-dipper sustained hypertensives have a two-fold greater risk of developing AF than dipper ones. This may be due to the fact that nighttime HTN may be a powerful determinant of long-standing left ventricular diastolic dysfunction, which subsequently increases atrial stretch. Furthermore, it has been observed that nighttime hemodynamics, are associated with higher sympathetic and reduced vagal activity, which may trigger AF. Additionally, sympathetic activation is associated with the stimulation of the renin-angiotensin-aldosterone axis (RAAA), which leads to increased left ventricular diastolic preload, both atrial and ventricular fibrosis, exerting thus direct cellular electrophysiological effects. Besides, scientists suggested that nighttime HTN is better associated with cardiovascular target organ damage (TOD) as compared with the non-dipping pattern.

According to the most recent guidelines of the ESH, the presence of microalbuminuria, increased pulse wave velocity, LVH on echocardiogram and carotid plaques detected during carotid ultrasonography, constitute markers of asymptomatic organ damage and it has been clearly demonstrated from multiple studies that they can predict CV mortality independently of SCORE stratification.

In our study we will try to investigate whether abnormalities in the circadian rhythm of BP (such as extreme dipping or non-dipping pattern, and/or morning surge) in hypertensive subjects with or without TOD are associated with the development of new-onset paroxysmal AF.

24-hr ambulatory BP monitoring (ABPM) along with the 24-hour blood pressure monitors with AF detector will help us to examine the incidence of AF in extremely dippers or non-dippers, and/or patients exhibiting a morning surge in BP, with or without TOD. Some of the questions that we aim to answer while conducting this study are whether an asymptomatic AF episode is more commonly detected in extreme dippers, non-dippers, or morning surgers, during daytime or during nighttime, or whether TOD is associated with asymptomatic AF episodes.

Importantly, Iqbal et al, demonstrated that there is an association between AF and nighttime DBP. On top of that, during the past decade, a research study conducted in 546 hypertensive subjects aged < 60 years of age and who were followed-up for 9.2 years, showed that DBP, whether 24-hr mean, daytime mean, or nighttime mean, provided the most incremental value for the prediction of morbid events. Thereby, we want to examine if AF episodes have any association with the 24hr systolic and the diastolic blood pressure (DBP) levels. It would also be interesting to observe for any associations between AF occurrence and the mean 24-hr ABPM and office heart rate (HR).

Moreover, it has been showed that pulse pressure (PP) determines left atrial enlargement in non-dipper patients with never-treated essential HTN. Thus, in our study, we will also examine whether a wide PP is associated with silent AF episodes in treated hypertensive subjects.

Summarizing, the goals of our study are to determine a).the association between abnormal circadian BP and the development of paroxysmal AF in hypertensive patients, b).at which level of TOD, paroxysmal AF episodes are detected in hypertensive subjects, c).if there is any association between systolic and/or diastolic BP levels with AF occurrence, d).whether the mean heart rate during a 24-hr interval is associated with the development of paroxysmal AF, and finally e).examine the relationship between a wide PP and asymptomatic AF episodes in patients with HTN.

Study Population We will evaluate all adult patients referred by their family physicians to the "Hypertension and Cardiovascular Prevention" Outpatient Clinic at Evangelismos General Hospital in Athens, from June 2015 to present.

All patients with an average office systolic BP ≥140 mmHg and/or an average diastolic BP ≥90 mmHg on three consecutive visits are considered as having essential HTN. Furthermore, individuals under treatment with one or more antihypertensive drug are also enrolled in the study.

Objectives Primary endpoint

• To investigate whether nighttime BP patterns (extreme dipping, normal dipping or reduced dipping and non-dipping including risers) or early morning surge are associated with the detection of paroxysmal AF in hypertensive subjects.

Further definitions Normal diurnal systolic and diastolic BP pattern: arterial BP has a daily variation characterized by substantial reductions during sleep, a rapid rise upon awakening, and increased variability during the awake period in ambulant normal subjects and hypertensive patients.

Reduced diurnal systolic and diastolic BP pattern: nocturnal systolic and/or DBP fall from 1 to 10% of daytime values or night/day systolic and/or diastolic BP ratio <1 and >0.9.

Nocturnal HTN: increased absolute level of night time systolic and/or diastolic BP (≥120/70 mmHg).19 Dipping pattern is defined as daytime-nighttime BP/daytime BP reduction - based on either ABP or home BP (HBP) monitoring- greater than 10% for systolic and/or diastolic BP. Nighttime HTN is defined as nighttime ABP or HBP ≥125/75 mmHg (systolic and/or diastolic).

Non-dipping and rising: no reduction or increase in nocturnal systolic and/or diastolic BP or night/day systolic and/or diastolic BP ratio ≥1.

Extreme dipping: marked nocturnal systolic and/or diastolic BP fall>20% of daytime systolic and/or diastolic values or night/day systolic and/or diastolic BP ratio <0.8.

Morning surge: excessive systolic and/or diastolic BP elevation rising in the morning.

Secondary endpoints

  • To detect asymptomatic and intermittent AF using a 24h ABPM with atrial fibrillation detector device and to compare its accuracy with Holter monitoring.
  • To investigate the agreement in the detection of paroxysmal AF using simultaneously the 24h-ABP with AF detection device and loop recording.
  • To observe at which level of TOD, asymptomatic AF episodes are more commonly detected.
  • To study if there is any relationship between systolic and/or diastolic BP levels with AF occurrence.
  • To examine whether office HR or mean HR using ABPM is associated with the development of silent AF episodes.
  • To examine whether a wide PP in ABPM is associated with the development of silent AF episodes.

Variables used to determine the primary and secondary endpoints

  • Sociodemographic data (birth date, gender, education level, employment status, place of residence, smoking status/habits, alcohol consumption)
  • Anthropometric characteristics (body weight, height, waist circumference)
  • Any abnormal findings on physical examination
  • Clinical relevant medical history and comorbidities
  • Concomitant medications
  • Electrocardiographic assessment
  • Investigation of TOD, including echocardiography, carotid artery triplex, 24h-urine albumin excretion and ABI
  • Recent laboratory testing results including hemoglobin, hematocrit, blood glucose, kidney and liver function tests
  • Management of HTN (pharmacologic and non-pharmacologic treatment)

Inclusion Criteria

  • Patients diagnosed with essential HTN (office BP>140/90mmHg) or patients receiving at least one antihypertensive medication (ie. RAAA inhibitors or diuretic), aged 18-85 years of age.
  • Patients with at least one of the following risk factors, organ damage or other evidence of cardiovascular disease:
  • Previous stroke
  • Transient ischemic attack (TIA)
  • Systemic embolism
  • Diabetes mellitus type 2
  • Obesity
  • Obstructive sleep apnea (OSA)
  • Dyslipidemia
  • History of coronary artery disease (CAD)
  • Valvular heart disease (VHD)
  • Echocardiographic findings attributed to HTN (ie. diastolic dysfunction, LVH)
  • White coat hypertension (WCH), masked hypertension (MH)
  • Positive family history for rhythm disturbances

Exclusion Criteria

  • Patients already diagnosed with paroxysmal or permanent AF
  • Severe renal insufficiency (eGFR according to MDRD formula <25ml/min/1.73m2)
  • Patients unable to attend follow-up visits
  • Clinical evidence of severe heart failure
  • Suspected secondary HTN
  • Mental disorders
  • Patients with cancer

The study protocol needs to be approved by the scientific board of the hospital and signed informed consent needs to be obtained from all participants.

Study Design We are going to conduct a cross-sectional, observational study.

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Attiki
      • Athens, Attiki, Greece, 10676
        • Evangelismos General Hospital
        • Contact:
        • Principal Investigator:
          • Emmanuel A. Andreadis, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

We will evaluate all adult patients referred by their family physicians to the "Hypertension and Cardiovascular Prevention" Outpatient Clinic at Evangelismos General Hospital in Athens, from June 2015 to present.

All patients with an average office systolic BP ≥140 mmHg and/or an average diastolic BP ≥90 mmHg on three consecutive visits are considered as having essential HTN. Furthermore, individuals under treatment with one or more antihypertensive drug are also enrolled in the study.

Description

Inclusion Criteria:

  • Patients diagnosed with essential HTN (office BP>140/90mmHg) or patients receiving at least one antihypertensive medication (ie. RAAA inhibitors or diuretic), aged 18-85 years of age.
  • Patients with at least one of the following risk factors, organ damage or other evidence of cardiovascular disease:
  • Previous stroke
  • Transient ischemic attack (TIA)
  • Systemic embolism
  • Diabetes mellitus type 2
  • Obesity
  • Obstructive sleep apnea (OSA)
  • Dyslipidemia
  • History of coronary artery disease (CAD)
  • Valvular heart disease (VHD)
  • Echocardiographic findings attributed to HTN (ie. diastolic dysfunction, LVH)
  • White coat hypertension (WCH), masked hypertension (MH)
  • Positive family history for rhythm disturbances

Exclusion Criteria:

  • Patients already diagnosed with paroxysmal or permanent AF
  • Severe renal insufficiency (eGFR according to MDRD formula <25ml/min/1.73m2)
  • Patients unable to attend follow-up visits
  • Clinical evidence of severe heart failure
  • Suspected secondary HTN
  • Mental disorders
  • Patients with cancer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Dippers

Dipping pattern is defined as daytime-nighttime BP/daytime BP reduction - based on either ABP monitoring- greater than 10% for systolic and/or diastolic BP.

Extreme dipping is marked nocturnal systolic and/or diastolic BP fall>20% of daytime systolic and/or diastolic values or night/day systolic and/or diastolic BP ratio <0.8.

Patients in this group will be dippers or extreme dippers. We aim to examine the association of this BP pattern with the development of asymptomatic episodes of paroxysmal atrial fibrillation, in hypertensive subjects.

Non-dippers

Non-dipping and rising: no reduction or increase in nocturnal systolic and/or diastolic BP or night/day systolic and/or diastolic BP ratio ≥1.

In this group we aim to examine whether an association exists between the non-dipping pattern and the development of asymptomatic episodes of paroxysmal atrial fibrillation in hypertensive subjects.

Morning Hypertensives

It is known that morning surge is the excessive systolic and/or diastolic BP elevation rising in the morning.

Patients in this group will have morning hypertension that is classified into two types:

the "morning-surge" type, characterized by a marked increase in blood pressure in the early morning, and the "nocturnal-hypertension" type, characterized by high blood pressure that persists from nighttime until early morning.

In our study we will examine whether an association between morning hypertension and asymptomatic episodes of paroxysmal atrial fibrillation exists in hypertensive subjects.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Association between nighttime BP patterns and/or early morning surge with the development of asymptomatic episodes of paroxysmal atrial fibrillation in hypertensive subjects
Time Frame: 12 months
• To investigate whether nighttime BP patterns (extreme dipping, normal dipping or reduced dipping and non-dipping including risers) or early morning surge are associated with the detection of paroxysmal AF in hypertensive subjects.
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Association between the degree of TOD and the development of paroxysmal AF in hypertensive patients
Time Frame: 12 months
• To observe at which level of TOD, asymptomatic AF episodes are more commonly detected.
12 months
Association between SBP and/or DBP levels with the development of paroxysmal AF in hypertensive patients
Time Frame: 12 months
• To study if there is any relationship between systolic and/or diastolic BP levels with AF occurrence.
12 months
Association between office heart rate or mean 24-hr heart rate with the development of asymptomatic paroxysmal AF episodes.
Time Frame: 12 months
• To examine whether office HR or mean HR using ABPM is associated with the development of silent AF episodes.
12 months
Association between PP and the development of asymptomatic paroxysmal AF episodes
Time Frame: 12 months
• To examine whether a wide PP in ABPM is associated with the development of silent AF episodes.
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2015

Primary Completion (Anticipated)

March 1, 2016

Study Completion (Anticipated)

September 1, 2016

Study Registration Dates

First Submitted

September 28, 2015

First Submitted That Met QC Criteria

September 28, 2015

First Posted (Estimate)

September 30, 2015

Study Record Updates

Last Update Posted (Estimate)

October 1, 2015

Last Update Submitted That Met QC Criteria

September 30, 2015

Last Verified

September 1, 2015

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension - Atrial Fibrillation

3
Subscribe